Is TransMedics Group Stock a Buy?

TransMedics Group (NASDAQ: TMDX) has emerged as a medical devices industry leader, capturing strong growth and climbing profitability from its organ transplant delivery system. Since the company's 2019 initial public offering, the stock has returned a massive 285%.That said, the early success hasn't been achieved without some stumbling blocks. The company's latest quarterly update came in below Wall Street estimates, and shares are down 49% from their 52-week high at the time of writing. The good news for TransMedics investors is that several factors still support a positive outlook, despite the volatility in the stock.Is now the time to add TransMedics Group stock to your portfolio? Here's what you need to know.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool